Routine risk minimization is heavily dependent on product prescribing labels (information for the prescriber) and medication guides (information for the patient) vetted by the approving regulatory agency. Additional routine risk minimization activities may include health care professional and patient educational programs, control access programs, controlled distribution systems, pregnancy prevention programs, and direct health care professional communications. 1 Challenges with the use of a prescribing label or patient information guide as the predominant methods for risk minimization include a misplaced confidence that a prescriber or patient has read the label/medication guide, understood the contents, and retained the acquired knowledge over time.
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Although labels categorize risks into pertinent sections such as contraindications, and warnings and precautions, the sheer volume of information contained within may add to the difficulty of discerning which identified or potential risks are considered important enough to necessitate additional patient work-up. Is the prescriber truly aware of the need to conduct lab tests before or during drug therapy to monitor and help prevent the occurrence of a serious risk? Has he or she paid careful attention to current or past medical history that may increase the potential for risk? Does the prescriber have a thorough awareness of serious potential drug interactions?
Once upon a time, a visit to the family practitioner for a check-up resulted in a battery of in-office examinations that are now seldom conducted in this era of high-patient-volume, fastpaced medicine. The ever-growing number of available medications and the limited amount of time a physician has to become familiar with a drug's safety profile add to the likelihood of a preventable serious adverse drug reaction. Sole reliance on the prescriber to ensure patient safety is not prudent. There also needs to be a commitment on behalf of the patient to contribute to his or her own understanding of the important risks. While there are a growing number of patients self-educating, owing to the aid of the internet and informational media programming, there still may be number of patients who do not read or understand the information provided to them or are not consistently receiving personalized information about their drug therapy. [2] [3] [4] Undoubtedly, product labels and medication guides have greatly contributed to risk minimization, especially with recent labeling format changes required by regulatory authorities that help offset and highlight important information. [5] [6] [7] On the other hand, these same regulatory authorities have stepped up efforts through newer guidance and legislation to measure the effectiveness of risk minimization efforts for both routine (primarily labeling text) and additional (beyond label methods) activities suggesting that more is needed. Regardless of the labeling format and the positioning of important safety information, the use of any label still must overcome the challenges outlined above. Then again, one may argue that routine risk minimization via labeling text and additional risk minimization activities are better than no interventions at all, so why spend time and resource measuring their effectiveness?
While regulatory agencies are requiring effectiveness measures, they have provided little guidance with respect to costefficient and dependable tools. Pharmaceutical companies are struggling with feasible and effective measurement options. Spontaneous adverse event reporting does not provide a true incidence rate which limits the value of trending. In addition, spontaneous adverse event reporting rates can be influenced by many other factors such as current newsworthy events that increase visibility and subsequent reporting at any given time. Moreover, exposure estimates are normally based on sales data from distribution facilities and do not represent actual usage. Additional prospective studies are very expensive, and epidemiological retrospective studies and registries must account for a host of variables that may have significantly influenced the occurrence of risk. Claims databases usually do not necessarily link the event with the drug, so results are based solely on inference. Surveys have been used, but questions remain regarding acceptable thresholds for prescriber/ patient understanding, flaws in survey design, different surveys used for similar products, and small cross-sections extrapolated to represent whole populations, to name a few. In addition, surveys are not routinely designed to correct and educate following an incorrect response.
Here, a new approach is proposed that is so compulsory that its effect cannot be questioned and therefore need not require a measurement of success. The first bastion for risk management must begin at the point of care. The health care provider should be obligated to work up a patient thoroughly before a drug is prescribed. Just as an anesthesiologist systematically runs through a set list of important information and questions with a patient prior to surgery, so should the prescriber of a new drug therapy.
To offset the challenges of information recall and time, physician order entry tools (stationary or handheld devices) for inoffice use should be developed that asks the prescriber a series of questions that correspond to the recommendations outlined in the contraindications and warnings and precautions sections of the product label for those risks deemed important by the regulatory authority. For example, a question may focus on whether or not a patient is pregnant or intends on becoming pregnant when prescribing a potentially teratogenic drug. It may ask if a pregnancy test has been performed and suggest that the prescription not be written until the results have been received. Marketing authorization holders would be obligated by health authority mandate to provide the necessary information for the order entry devices in an approved standardized format. Log entries would be recorded and kept on file at the prescriber's office.
A similar approach would involve the patient or the patient's personal care giver/family member. When a prescription is written for a new medication, deemed by the health authority to have a significant risk that should be communicated to and understood by the patient or care giver, a stationary or handheld device could be used to help educate. Following the one-on-one interaction with the prescriber, the patient would view a presentation that outlines the important risks and any information that he or she should communicate to the prescriber such as a pre-existing disease or condition that contraindicates its use. Once the presentation is complete, the patient or caregiver would be asked a series of questions confirming the understanding of the risks. The results would be printed out and returned to the appropriate office representative and assessed for the level of understanding. If needed, the office representative would consult with the prescriber and/or assist and educate the patient to improve the level of understanding before the patient leaves the office.
Outputs for both prescriber and patient devices can be retained and archived at the office. Trending analyses can be done electronically, maintaining anonymity if so desired, but should not be required due to the compulsory nature of the process.
Besides the elimination for the need of an effectiveness measure, other benefits may include a record of steps taken to reduce the potential for serious risks that may aid the prescriber should legal action result from the occurrence of a serious adverse reaction, and educating the patient about a risk prior to leaving the office allowing the patient to refuse a prescription if he or she became aware of a pre-existing condition that may increase his or her chances of experiencing the adverse event. The prescriber may be able to write for a different medication with less risk. Pharmacies cannot accept a return once the filled prescription leaves the pharmacy, so reading a medication guide after you get the drug home can be rather expensive and require a lot of unnecessary interaction with an insurance company.
Critiques of these proposals may include ''the burden placed on the existing health care system'' and the added costs, which are legitimate concerns. However, it should be made clear that the focus should be on risks determined by the health authority to warrant such an approach. Not all risks need be included, just those that rise to the level of a warranted action to prevent a serious outcome (eg, teratogenicity, hospitalization, or death).
Enormous advances in technology and global availability must be leveraged to combat the status quo mentality. We should not resist implementation because the technology may not be available in all territories, but rather implement as a standard that others should strive to achieve. We must consider the cost of these types of preventative programs versus the cost of treating a preventable serious adverse reaction.
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